BASEL, Switzerland, October 29 /PRNewswire/ -- A new study on pain published today has found that subcutaneous (SC) injections of the new renal anaemia therapy MIRCERA is associated with significantly ...
-- First Publication of Phase III Data in the Clinical Journal of the American Society of Nephrology Results from a multi-centre renal anaemia study show that switching patients directly from frequent ...
Roche announced today that the U.S. Food and Drug Administration (FDA) has approved Mircera (methoxy polyethylene glycol-epoetin beta) for the treatment of anaemia associated with chronic kidney ...
Overview: Mircera is used to treat anemia. Common side effects include diarrhea and pain or swelling in the nose or throat. Serious side effects are rare but include blood clots, seizures, and severe ...
The approval was based on an open-label, multiple dose, multicenter, dose-finding study in 64 pediatric patients with CKD who were on hemodialysis and who had stable hemoglobin levels while previously ...
US regulators have given the green light to Roche's new anaemia drug Mircera, but no launch across the Atlantic is likely for some time as the Swiss firm is embroiled in a legal dispute it is losing ...
being a common adverse event and a burden for patients with chronic kidney disease (CKD).
three times a week for the maintenance treatment of anaemia. The study results showed: - Minute changes in patients' haemoglobin (Hb) levels from baseline to evaluation (-0.131g/dL for MIRCERA once ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback